Cepheid - CPHD - Financial Statement Analysis

All financial statement analysis reports for your requested company can be accessed below. The SIC # column is the SIC Code for the industry under which the current company is analyzed. When a report is purchased the SIC Code indicated is the industry that the company displayed will be compared against. If a different industry is desired for comparison, purchase of a separate industry analysis is suggested.

In addition to the ratio analysis reports, the latest business news headlines involving your company or industry sector are hyperlinked for your convenience along with the stock ticker for the company displayed.

Financial statement analysis updated: May 19, 2013

Cepheid - SIC # 3826

Ticker	Exchange	SIC #	Website	Latest Ticker
CPHD	Nasdaq	3826	http://www.cepheid.com/	38.09 -0.14
Select one of the five (5) financial statement analysis reports below to view the ratio analysis report for your selected company: Publicly Traded Company Industry Ratios Publicly Traded Company VS. Industry Ratios Publicly Traded Company VS Publicly Traded Company Private Company VS Publicly Traded Company
Latest Headlines for Cepheid Primecap Rides Health to Top Growth Fund: Riskless Return - May 14th, 2013 10:00 pm Neutral Rating Restated for Cepheid - May 13th, 2013 12:20 pm CEPHEID Financials - May 10th, 2013 11:04 am Cepheid Welcomes Executive Vice President of Global Operations - May 7th, 2013 2:05 pm CEPHEID Files SEC form 8-K, Entry into a Material Definitive Agreement, Change in Directors or Principal Officers, Fi - May 7th, 2013 7:16 am DexCom Loss Narrower than Est. - May 2nd, 2013 11:40 am CEPHEID Files SEC form 8-K, Submission of Matters to a Vote of Security Holders - May 2nd, 2013 8:31 am CEPHEID Files SEC form 10-Q, Quarterly Report - May 2nd, 2013 7:08 am Cepheid to Webcast Upcoming Financial Presentations - May 1st, 2013 2:05 pm ResMed's Earnings Beat; Revs Lag - Apr 29th, 2013 11:40 am FDA Taking More Aggressive Approach in Areas of Totally Unmet Medical Need, Granting Breakthrough Status to New Drugs in Development if No Other Therapeutic Option - Apr 26th, 2013 10:50 am Target Executive Officer Sells More Than 41K Shares and 4 Insider Sales to Note - Apr 24th, 2013 7:13 am Did These Stocks Miss or Beat Analyst Expectations? - Apr 21st, 2013 11:46 am Covidien Expands Shiley Offerings - Apr 19th, 2013 12:20 pm FDA Nod for Luminex Offering - Apr 19th, 2013 11:40 am Cepheid Earnings Beat, Retains Outlook - Apr 19th, 2013 8:50 am Cepheid should be bought into strength, says RW Baird - Apr 19th, 2013 6:45 am Cepheid Management Discusses Q1 2013 Results - Earnings Call Transcript - Apr 18th, 2013 7:20 pm Cepheid posts 1Q profit as sales improve - Apr 18th, 2013 4:34 pm Cepheid Earnings: Here’s Why Investors are Excited Now - Apr 18th, 2013 3:19 pm View All Current Headlines >>